OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary Jacob, Ph.D., Chief Executive Officer of Okyo Pharma, commented: “We are thrilled to announce that OK-101 has been granted the name urcosimod, marking an important step in its development as a therapeutic option for patients suffering from serious ocular conditions. Urcosimod is currently in a Phase 2 clinical trial for neuropathic corneal pain, an area of significant unmet medical need. This follows the encouraging results observed in our prior Phase 2 trial of urcosimod for dry eye disease, where the drug demonstrated strong pain reducing effects and a favorable safety profile.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges
- OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence
- Okyo Pharma CEO purchases 10,000 shares of company
- OKYO Pharma Advances Clinical Trials with Encouraging Interim Results
- Okyo Pharma to complete enrollment of NCP trial by end of Q2, OK-101 update
Questions or Comments about the article? Write to editor@tipranks.com